Eurofins CDMO vs Minaris Advanced Therapies: CDMO Comparison
Side-by-side comparison of Eurofins CDMO and Minaris Advanced Therapies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Eurofins CDMO has more FDA inspections on record (4 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Minaris Advanced Therapies holds 2 active EMA GMP certificates; Eurofins CDMO does not appear in EudraGMDP.
- Minaris Advanced Therapies maintains 4 MHRA / UK GMP certificates; Eurofins CDMO does not.
On a 13-modality CDMO landscape, both Eurofins CDMO and Minaris Advanced Therapies qualify as Cell Therapy manufacturers; Minaris Advanced Therapies carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Eurofins CDMO and Minaris Advanced Therapies qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Eurofins CDMO vs Minaris Advanced Therapies
Which has the stronger FDA inspection record, Eurofins CDMO or Minaris Advanced Therapies?
Both Eurofins CDMO and Minaris Advanced Therapies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Eurofins CDMO has 4 FDA inspections on record; Minaris Advanced Therapies has 1.
How do Eurofins CDMO and Minaris Advanced Therapies compare on European GMP coverage?
Eurofins CDMO holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Minaris Advanced Therapies holds 2 active EMA GMP certificates and 4 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Cell Therapy manufacturing — Eurofins CDMO or Minaris Advanced Therapies?
Both Eurofins CDMO and Minaris Advanced Therapies are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Eurofins CDMO carries a Signal Score of 82/100 and Minaris Advanced Therapies carries 84/100 — essentially tied for Minaris Advanced Therapies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →